Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool™ RF Ablation System

Prevail Drug Coated Balloon Catheter Launches in Europe

Prevail Drug coated balloon catheter is used during percutaneous coronary intervention procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease.

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

April 27, 2017

Medtronic Canada, a subsidiary of Medtronic plc (NYSE:MDT), today announced Health Canada licensing and the launch of the OsteoCool™ RF Ablation System in Canada.

For physicians who treat patients with painful bone metastases, the OsteoCool System is currently the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities — providing procedural flexibility and predictable, customized treatment. Cooled RF ablation uses high-frequency energy to target cancer cells.

In 2016, an estimated 202,400 Canadians developed cancer.1 Metastatic bone disease occurs in 60-80 percent of cancer patients, most frequently among patients with primary malignancies of the breast, prostate, liver, and lung.2 Seventy percent of metastatic bone cancer patients develop at least one lesion in the spine.3

The OsteoCool RF Ablation System offers a valid option for patients with painful bone tumors when conventional therapies are considered ineffective, too slow-acting or cause unacceptable side effects.4

“Osteocool Radiofrequency Ablation provides a minimally invasive option for the treatment of painful bone metastases and is particularly useful in patients that have not responded well to other treatment modalities,” said Dr. Roy Park in EFW Radiology in Calgary.

“Our Pain Therapies business is deeply rooted in the Medtronic Mission — which calls us to alleviate pain,” said Sandrine Moirez, senior director, Restorative Therapy Group, at Medtronic Canada. “We put an important treatment option into the hands of physicians so they can help more patients suffering from debilitating cancer pain.”

Medtronic acquired the OsteoCool technology and associated intellectual property from Baylis Medical on December 16, 2015, and partnered with the company to further innovate the system. Baylis continues to manufacture OsteoCool in Mississauga, Ontario.

The system is temperature controlled and uses internally water-cooled probes to prevent overheating of surrounding tissue during the procedure. The 17-gauge, bipolar probes are available in three lengths and may be used through a variety of cannula sizes. Because two OsteoCool RF ablation probes can be used simultaneously, the system supports a variety of ablation scenarios, accommodating unique patient and procedural needs.

spot_img

DON'T MISS

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.